Discussion: View Thread

DIA Statistics Forum Program Now Available

  • 1.  DIA Statistics Forum Program Now Available

    Posted 12-15-2011 18:03

    Dear Consulting section members:

    If you are interested in being part of a dialog with FDA and with Industry statisticians on topics of relevance to both, you may want to consider attending the FDA/DIA statistics forum. The program is ready for the 2012 FDA/DIA Statistics Forum April 23-25 in DC:

    http://www.diahome.org/DIAHome/resources/content.aspx?type=eopdf&file=%2fproductfiles%2f27919%2f12008%2Epdf

    Including ...

    Keynotes:

    Lisa LaVange, PhD, Director, Office of Biostatistics, CDER, FDA, and

    Robert Hemmings, Statistics Unit Manager, Medicines and Healthcare products, Regulatory Agency (MHRA), UK

    Session Topics:

    FDA Guidances: Multiple Endpoints in Clinical Trials and Non-Inferiority Clinical Trials

    Safety assessments during the pre- and post-marketing phases

    Novel approaches to establishing trust in data monitoring committees

    Tailored Therapeutics

    Clinical trial outcome assessments and good measurement science

    Subgroup analysis in clinical trials

    Enrichment designs

    Tutorials:

    Multiplicity in Clinical Trials taught by Alex Dmitrienko, PhD

    Data Monitoring Committees co-taught by David DeMets, Ph.D. and Susan Ellenberg, Ph.D

    Please note: to give as many of you as is possible an opportunity "to be part" of this year's meeting, we are also featuring/promoting, a Poster Session and Round Tables!

    This is a co-sponsored FDA/DIA meeting designed by FDA and Industry statisticians to talk about the "stuff" we need we need to figure out and know. Please mark your calendars, register (with very special rates for Govt. attendees) and join us in April to think and to learn!

    May you and yours have a Great Holiday Season and a Very Happy New Year!

    Many regards,

    The 2012 FDA/DIA Statistics Forum Steering Committee

    Stephen E. Wilson, DrPH, CAPT, USPHS, CDER, FDA (co-chair)

    Barry Schwab, PhD, Janssen Research & Development, LLC (co-chair)

    Joan Buenconsejo, PhD, CDER, FDA

    Christy Chuang-Stein, PhD, Pfizer Inc.

    José C. Pinheiro, PhD, Janssen Research & Development, LLC

    Estelle Russek-Cohen, PhD, CBER, FDA

    Jerald S. Schindler, DrPH, Merck Research Laboratories

    Ram C. Tiwari, PhD, CDER, FDA

    Joachim Vollmar, MS, International Clinical Development Consultants LLC (European Representative)

     

    Program Manager

    Ellen Diegel, DIA